Ipilimumab

Generic Name: Ipilimumab

Brand Names: Yervoy

Drug Type: Biotech

Chemical Formula: -

CAS Number: 477202-00-9

Unique Ingredient Identifier: 6T8C155666

Background: Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Indication: Ipilimumab is indicated in the following cancerous conditions:

Melanoma

Renal Cell Carcinoma (RCC)

Colorectal Cancer

Hepatocellular Carcinoma

Non-Small Cell Lung Cancer (NSCLC)

Malignant Pleural Mesothelioma

Esophageal Cancer
...

Associated Conditions: Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)

Associated Therapies: First Line Chemotherapy

Clinical Trials

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Phase 2

Recruiting

Conditions: Metastatic Nasopharyngeal Carcinoma
Recurrent Nasopharyngeal Carcinoma
Stage IV Nasopharyngeal Carcinoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cabozantinib S-malate
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2023-06-15

Last Posted Date: 2024-12-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT05904080

Locations: 🇺🇸
Methodist Jennie Edmundson Hospital, Council Bluffs, Iowa, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 74 locations

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Phase 1

Recruiting

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Melanoma
Metastatic Merkel Cell Carcinoma
Unresectable Basal Cell Carcinoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Carcinoma in the Skin
Metastatic Basal Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Ipilimumab
Procedure: Kidney Biopsy
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab
Drug: Prednisone
Drug: Sirolimus

First Posted Date: 2023-06-09

Last Posted Date: 2024-12-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT05896839

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 21 locations

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Phase 2

Recruiting

Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma
Locally Advanced Leiomyosarcoma
Locally Advanced Liposarcoma
Locally Advanced Undifferentiated Pleomorphic Sarcoma
Locally Advanced Unresectable Soft Tissue Sarcoma
Metastatic Undifferentiated Pleomorphic Sarcoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cabozantinib
Biological: Ipilimumab
Procedure: Magnetic Resonance Imaging
Biological: Nivolumab

First Posted Date: 2023-05-01

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 66

Registration Number: NCT05836571

Locations: 🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 21 locations

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Phase 2

Recruiting

Conditions: Metastatic Melanoma
Skin Cancer

Interventions: Drug: Ipilimumab
Drug: Nivolumab
Procedure: Cryoablation

First Posted Date: 2023-03-22

Last Posted Date: 2024-03-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 37

Registration Number: NCT05779423

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Immunotherapy in Patients With Early dMMR Rectal Cancer

Phase 2

Recruiting

Conditions: Cancer of Rectum

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2023-02-17

Last Posted Date: 2024-04-03

Lead Sponsor: Odense University Hospital

Target Recruit Count: 39

Registration Number: NCT05732389

Locations: 🇩🇰
Department of Oncology, Odense University Hospital, Odense, Denmark

Nivolumab with Ipilimumab Combined with TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer

Phase 1

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Radiation: SBRT
Biological: TGFβ-B-15 peptide

First Posted Date: 2023-02-10

Last Posted Date: 2024-10-01

Lead Sponsor: Inna Chen, MD

Target Recruit Count: 20

Registration Number: NCT05721846

Locations: 🇩🇰
Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2023-02-06

Last Posted Date: 2024-01-16

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 108

Registration Number: NCT05715229

Locations: 🇺🇸
John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Early Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma
Metastasis to Brain

Interventions: Drug: Nivolumab
Drug: Nivolumab + Relatlimab
Procedure: Standard of Care Craniotomy
Drug: Ipilimumab

First Posted Date: 2023-01-30

Last Posted Date: 2024-12-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 1

Registration Number: NCT05704933

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Phase 2

Recruiting

Conditions: Pleural Biphasic Mesothelioma
Pleural Sarcomatoid Mesothelioma

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Procedure: Surgical Procedure
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2022-12-12

Last Posted Date: 2024-10-26

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 26

Registration Number: NCT05647265

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States

and more 120 locations

A Study of ANV419 Alone or in Combination with Approved Treatment in Patients with Cutaneous Melanoma (OMNIA-1).

Phase 1

Completed

Conditions: Melanoma (Skin)
Cutaneous Melanoma
Adult Disease
Advanced Solid Tumor
Metastatic Melanoma

Interventions: Drug: ANV419
Drug: Ipilimumab
Drug: Pembrolizumab

First Posted Date: 2022-10-13

Last Posted Date: 2024-11-27

Lead Sponsor: Anaveon AG

Target Recruit Count: 29

Registration Number: NCT05578872

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 22 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy